CureVac Trading Down 2.5 % Shares of NASDAQ:CVAC opened at $3.12 on Monday. The business has a 50 day moving average of $3.08 and a two-hundred day moving average of $3.17. The company has a ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

With insights from industry leaders like CEPI, Merck, CureVac, BioNTech, and more, this guide is essential for staying competitive in mRNA process development and manufacturing. Download your copy ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Bojan Pancevski is The Wall Street Journal’s chief European political correspondent, covering European and global affairs. He ...

The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday. March 10, 2025 BioNTech guides for worse-than ...

DelveInsight's "Metastatic Cutaneous Squamous Cell Cancer Market Insights, Epidemiology, and Market Forecast- 2032" report ...